5 December 2025: Reference is made to the stock exchange announcements published
by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, and
subsequent announcements, regarding the contemplated fully underwritten rights
issue of 260,000,000 new shares in the Company (the "Offer Shares") raising
gross proceeds of NOK 130 million (the "Rights Issue").

An extraordinary general meeting of the Company was held today, 5 December 2025,
by electronic means through Lumi AGM. The general meeting, inter alia, resolved
(i) the approval of an audited interim balance sheet, (ii) the share capital
reduction required to carry out the Rights Issue, and (iii) to ratify and update
the resolution to increase the share capital in connection with the Rights Issue
adopted at the general meeting of the Company on 4 August 2025.

It is expected that the share capital increase pertaining to the Rights Issue
will be registered with the Norwegian Register of Business Enterprises on or
about 9 December 2025. The Offer Shares are expected to commence trading on the
Oslo Stock Exchange on or about 10 December 2025.

The complete minutes of the extraordinary general meeting are attached to this
release and are also available on the Company's website,
https://www.oncoinvent.com/.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email: soug@oncoinvent.com

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases in the peritoneum post-surgery, harnessing the benefits of
modern radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial in ovarian cancer is
currently ongoing in the US and Europe. Early clinical efficacy data are highly
encouraging, and no serious toxicity or safety concerns have been reported to
date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo
Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly
target microscopic metastases in the abdominal cavity following surgery.
Radspherin® is currently in development as a post-surgical treatment for
patients with cancer that has spread to the abdominal cavity - a group with very
limited treatment options today. The drug candidate offers a distinctly unique
therapeutic approach with several differentiating features, including the use of
radium-224, single-dose treatment with a sustained therapeutic effect, non
-systemic administration, direct targeting and an exceptional dose-to-tumor
ratio, maximizing efficacy while limiting harm to healthy tissue